Evidence map›Paper›PMID 40198713›Full record

ArticlePLoS pathogens2025

A targeted CRISPR screen identifies ETS1 as a regulator of HIV-1 latency.

Manickam Ashokkumar, Terry L Hafer, Abby Felton, Nancie M Archin, David M Margolis, Michael Emerman, Edward P Browne

Abstract read
In one paragraph

Article in PLoS pathogens, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Review
  6. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

7 authors.

Manickam AshokkumarDepartment of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States of America.ORCID 0000-0002-7880-9497
Terry L HaferDivision of Basic Sciences, Fred Hutchinson Cancer Center, Seattle, Washington, United States of America.
Abby FeltonDivision of Basic Sciences, Fred Hutchinson Cancer Center, Seattle, Washington, United States of America.
Nancie M ArchinDepartment of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States of America.
David M MargolisDepartment of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States of America.
Michael EmermanDivision of Basic Sciences, Fred Hutchinson Cancer Center, Seattle, Washington, United States of America.
Edward P BrowneDepartment of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States of America.ORCID 0000-0001-9070-7015

Funding

Collaboratory of AIDS Researchers for Eradication (CARE)UM1AI164567 · NIAID · UNIV OF NORTH CAROLINA CHAPEL HILL · PI DAVID M. MARGOLIS · 2021 to 2026
$31.6M
HIV-CRISPR: A novel approach to the comprehensive discovery of HIV latency factorsDP1DA051110 · NIDA · FRED HUTCHINSON CANCER RESEARCH CENTER · PI EMERMAN, MICHAEL · 2020 to 2024
$4.4M
Regulation of HIV Latency by Host Cell Transcriptional and Epigenetic NetworksR01AI143381 · NIAID · UNIV OF NORTH CAROLINA CHAPEL HILL · PI BROWNE, EDWARD P · 2019 to 2022
$1.6M
NIAID NIH HHS R01 AI143381NIAID NIH HHS UM1 AI164567NIDA NIH HHS DP1 DA051110
6 · The paper itself

Abstract

Human Immunodeficiency virus (HIV) infection is regulated by a wide array of host cell factors that combine to influence viral transcription and latency. To understand the complex relationship between the host cell and HIV-1 latency, we performed a lentiviral CRISPR screen that targeted a set of host cell genes whose expression or activity correlates with HIV-1 expression. We further investigated one of the identified factors - the transcription factor ETS1, and found that it is required for maintenance of HIV-1 latency in both latently infected cell lines and in a primary CD4 T cell latency model. Interestingly, ETS1 played divergent roles in actively infected and latently infected CD4 T cells, with knockout of ETS1 leading to reduced HIV-1 expression in actively infected cells, but increased HIV-1 expression in latently infected cells, indicating that ETS1 can play both a positive and negative role in HIV-1 expression. CRISPR/Cas9 knockout of ETS1 in CD4 T cells from ART-suppressed people with HIV-1 (PWH) confirmed that ETS1 maintains transcriptional repression of the clinical HIV-1 reservoir. Transcriptomic profiling of ETS1-depleted cells from PWH identified a set of host cell pathways involved in viral transcription that are controlled by ETS1 in resting CD4 T cells. In particular, we observed that ETS1 knockout increased expression of the long non-coding RNA MALAT1 that has been previously identified as a positive regulator of HIV-1 expression. Furthermore, the impact of ETS1 depletion on HIV-1 expression in latently infected cells was partially dependent on MALAT1. Additionally, we demonstrate that ETS1 knockout resulted in enhanced abundance of activating modifications (H3K9Ac, H3K27Ac, H3K4me3) on histones located at the HIV-1 long terminal repeat (LTR), indicating that ETS1 regulates the activity of chromatin-targeting complexes at the HIV-1 LTR. Overall, these data demonstrate that ETS1 is an important regulator of HIV-1 latency that impacts HIV-1 expression through repressing MALAT1 expression and by regulating modification of proviral histones.

Indexed as

CD4-Positive T-LymphocytesHIV-1HIV InfectionsProto-Oncogene Protein c-ets-1Virus LatencyClustered Regularly Interspaced Short Palindromic RepeatsCRISPR-Cas SystemsGene Expression Regulation, ViralHumansETS1 protein, humanProto-Oncogene Protein c-ets-1

Identifiers

PMID40198713
PMCPMC12005537

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.